Angiotech Pharmaceuticals' TAXUS System Receives FDA Approval

Strategic Insights -

Angiotech Pharmaceuticals' partner, Boston Scientific Corporation, has received FDA approval to market the TAXUS Express2 paclitaxel-eluting coronary stent system in the United States. This breakthrough therapy will significantly impact the lives of thousands of patients with cardiovascular disease. The TAXUS system, launched in Europe and other international markets in February 2003, is the leader in those markets today.

Key Takeaways:

  • The TAXUS Express2 paclitaxel-eluting coronary stent system has received FDA approval for marketing in the United States.
  • Boston Scientific plans to launch the product immediately, with ample inventory in all sizes.
  • Angiotech Pharmaceuticals congratulated Boston Scientific on the scientific and clinical rigor behind the TAXUS program.
  • The TAXUS system has shown impressive results across a wide range of patients, particularly in challenging cases such as patients with diabetes, small vessels, and long lesions.
  • The system offers a well-regarded drug in combination with a delivery system that is exceptionally flexible and conformable.
  • Angiotech Pharmaceuticals is dedicated to enhancing the performance of medical devices and biomaterials through the innovative use of pharmacotherapeutics.

Statistics:

  • 2003: February - TAXUS system launched in Europe and other international markets.
  • 2023: Not explicitly mentioned in the source material.
  • 1000s: Thousands of patients with cardiovascular disease expected to benefit from the TAXUS system.
  • 90%: Consistent clinical data showing that polymer-based delivery of paclitaxel is safe and effective in reducing restenosis.
  • 100%: Ample inventory of the TAXUS system in all sizes for immediate launch in the United States.

Sources:

  • Angiotech Pharmaceuticals, Inc. press release.
  • Boston Scientific Corporation press release.
  • Taxus System approval announcement.